amiodarone has been researched along with Cardiovascular Diseases in 49 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dronedarone restores sinus rhythm and reduces hospitalization or death in intermittent atrial fibrillation." | 9.15 | Dronedarone in high-risk permanent atrial fibrillation. ( Afzal, R; Alings, M; Amerena, J; Atar, D; Avezum, Á; Baret-Cormel, L; Blomström, P; Borggrefe, M; Budaj, A; Camm, AJ; Chen, SA; Ching, CK; Chrolavicius, S; Commerford, P; Connolly, SJ; Dans, A; Davy, JM; Delacrétaz, E; Di Pasquale, G; Diaz, R; Dorian, P; Flaker, G; Golitsyn, S; Gonzalez-Hermosillo, A; Granger, CB; Halperin, JL; Heidbüchel, H; Hohnloser, SH; Joyner, C; Kautzner, J; Kim, JS; Lanas, F; Lewis, BS; Merino, JL; Morillo, C; Murin, J; Narasimhan, C; Paolasso, E; Parkhomenko, A; Peters, NS; Sim, KH; Staiger, C; Stiles, MK; Tanomsup, S; Toivonen, L; Tomcsányi, J; Torp-Pedersen, C; Tse, HF; Vardas, P; Vinereanu, D; Weinling, E; Xavier, D; Yusuf, S; Zhu, J; Zhu, JR, 2011) |
| "Dronedarone is a new antiarrhythmic drug that is being developed for the treatment of patients with atrial fibrillation." | 9.14 | Effect of dronedarone on cardiovascular events in atrial fibrillation. ( Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C; van Eickels, M, 2009) |
| "In a multicenter study with a double-blind design, we planned to randomly assign 1000 patients who were hospitalized with symptomatic heart failure and severe left ventricular systolic dysfunction to receive 400 mg of dronedarone twice a day or placebo." | 9.13 | Increased mortality after dronedarone therapy for severe heart failure. ( Amlie, J; Carlsen, J; Crijns, H; Gøtzsche, O; Køber, L; Lévy, S; McMurray, JJ; Torp-Pedersen, C, 2008) |
| "Dronedarone is a new antiarrhythmic currently approved for use among patients with nonpermanent atrial fibrillation (AF) based on the positive results of the ATHENA trial." | 8.88 | Dronedarone in atrial fibrillation: the aftermath of the PALLAS trial. ( Salam, AM, 2012) |
| "Cardiovascular manifestations of thyrotoxicosis and thyroid dysfunction caused by amiodarone." | 8.82 | [Cardiovascular manifestations of thyrotoxicosis and thyroid dysfunction caused by amiodarone]. ( Barta, K; Lorincz, I; Nagy, E; Simkó, J; Szabó, Z; Varga, E, 2004) |
| "Rivaroxaban reduces the risk of thromboembolism in atrial fibrillation (AF) patients, who often also receive antiarrhythmic drugs (AADs) to maintain sinus rhythm." | 8.02 | Safety and Effectiveness of Rivaroxaban in Combination with Various Antiarrhythmic Drugs in Patients with Non-Permanent Atrial Fibrillation. ( Chen, CY; Chiou, WR; Chuang, JY; Huang, CC; Kuo, JY; Lee, YH; Liao, FC; Lin, PL; Liu, LY; Su, MI; Tsai, CT; Wu, YJ, 2021) |
| "We present a case of severe acute kidney injury (AKI) occurring shortly after the initiation of dronedarone therapy, which we suspect was the result of an adverse drug reaction." | 7.79 | Reversible acute kidney injury requiring haemodialysis five days after starting dronedarone in a stable 71-year-old man at risk of cardiovascular polypharmacy. ( Leaver, L; Maruthappu, M; Wayne, RP; Young, C, 2013) |
| "The ATHENA clinical trial enrolled 4,628 patients in 37 countries and evaluated the efficacy of dronedarone 400 mg twice daily versus placebo for the prevention of cardiovascular hospitalisation or death from any cause in patients with paroxysmal or persistent atrial fibrillation or atrial flutter." | 7.79 | Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland. ( Åkerborg, Ö; Bégo-Le Bagousse, G; Lindgren, P; Nilsson, J; Rosenquist, M, 2013) |
| "Amiodarone-induced thyrotoxicosis (AIT) is a clinical condition that is notoriously difficult to manage; the relative risk of adverse cardiovascular events in these patients compared with euthyroid patients is largely unknown." | 7.75 | Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome. ( Chow, WH; Fan, K; Jim, MH; Lee, CH; Mok, M; Shea, YF; Siu, CW; Tse, HF; Yiu, KH; Yuen, M, 2009) |
| "Dronedarone has also been shown to reduce ventricular rate and the incidence of hospitalization due to cardiovascular events." | 6.47 | The management of patients with atrial fibrillation and dronedarone's place in therapy. ( Boiangiu, C; Cohen, M, 2011) |
| "Dronedarone is a new multichannel blocker, structurally related to amiodarone but free of iodine and less lipophilic and so expected to be free of iodine-related organ toxicity and tissue accumulation." | 5.36 | Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials. ( Duray, GZ; Hohnloser, SH; Schmitt, J, 2010) |
| "Dronedarone restores sinus rhythm and reduces hospitalization or death in intermittent atrial fibrillation." | 5.15 | Dronedarone in high-risk permanent atrial fibrillation. ( Afzal, R; Alings, M; Amerena, J; Atar, D; Avezum, Á; Baret-Cormel, L; Blomström, P; Borggrefe, M; Budaj, A; Camm, AJ; Chen, SA; Ching, CK; Chrolavicius, S; Commerford, P; Connolly, SJ; Dans, A; Davy, JM; Delacrétaz, E; Di Pasquale, G; Diaz, R; Dorian, P; Flaker, G; Golitsyn, S; Gonzalez-Hermosillo, A; Granger, CB; Halperin, JL; Heidbüchel, H; Hohnloser, SH; Joyner, C; Kautzner, J; Kim, JS; Lanas, F; Lewis, BS; Merino, JL; Morillo, C; Murin, J; Narasimhan, C; Paolasso, E; Parkhomenko, A; Peters, NS; Sim, KH; Staiger, C; Stiles, MK; Tanomsup, S; Toivonen, L; Tomcsányi, J; Torp-Pedersen, C; Tse, HF; Vardas, P; Vinereanu, D; Weinling, E; Xavier, D; Yusuf, S; Zhu, J; Zhu, JR, 2011) |
| "Dronedarone is a new antiarrhythmic drug that is being developed for the treatment of patients with atrial fibrillation." | 5.14 | Effect of dronedarone on cardiovascular events in atrial fibrillation. ( Connolly, SJ; Crijns, HJ; Gaudin, C; Hohnloser, SH; Page, RL; Torp-Pedersen, C; van Eickels, M, 2009) |
| "In a multicenter study with a double-blind design, we planned to randomly assign 1000 patients who were hospitalized with symptomatic heart failure and severe left ventricular systolic dysfunction to receive 400 mg of dronedarone twice a day or placebo." | 5.13 | Increased mortality after dronedarone therapy for severe heart failure. ( Amlie, J; Carlsen, J; Crijns, H; Gøtzsche, O; Køber, L; Lévy, S; McMurray, JJ; Torp-Pedersen, C, 2008) |
| "Dronedarone is a new antiarrhythmic currently approved for use among patients with nonpermanent atrial fibrillation (AF) based on the positive results of the ATHENA trial." | 4.88 | Dronedarone in atrial fibrillation: the aftermath of the PALLAS trial. ( Salam, AM, 2012) |
| " Treatment with amiodarone may lead to changes in thyroid tests results and to development of hypothyroidism or thyrotoxicosis." | 4.82 | [Thyroid and cardiovascular disorders]. ( Gajek, J; Zyśko, D, 2004) |
| "Cardiovascular manifestations of thyrotoxicosis and thyroid dysfunction caused by amiodarone." | 4.82 | [Cardiovascular manifestations of thyrotoxicosis and thyroid dysfunction caused by amiodarone]. ( Barta, K; Lorincz, I; Nagy, E; Simkó, J; Szabó, Z; Varga, E, 2004) |
| "Amiodarone prophylaxis decreases the occurrence of atrial fibrillation, ventricular tachyarrhythmias, and stroke and length of stay after cardiac surgery." | 4.82 | Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis. ( Aasbo, JD; Kim, MH; Krishnan, K; Lawrence, AT; Trohman, RG, 2005) |
| "Rivaroxaban reduces the risk of thromboembolism in atrial fibrillation (AF) patients, who often also receive antiarrhythmic drugs (AADs) to maintain sinus rhythm." | 4.02 | Safety and Effectiveness of Rivaroxaban in Combination with Various Antiarrhythmic Drugs in Patients with Non-Permanent Atrial Fibrillation. ( Chen, CY; Chiou, WR; Chuang, JY; Huang, CC; Kuo, JY; Lee, YH; Liao, FC; Lin, PL; Liu, LY; Su, MI; Tsai, CT; Wu, YJ, 2021) |
| " Amiodarone induced hypothyroidism is treated with levothyroxine and amiodarone taking is not interrupted." | 3.96 | Pharmacologically induced thyreopathy in patients with cardiovascular disease. ( Brutvan, T; Ježková, J; Krátký, J, 2020) |
| "We present a case of severe acute kidney injury (AKI) occurring shortly after the initiation of dronedarone therapy, which we suspect was the result of an adverse drug reaction." | 3.79 | Reversible acute kidney injury requiring haemodialysis five days after starting dronedarone in a stable 71-year-old man at risk of cardiovascular polypharmacy. ( Leaver, L; Maruthappu, M; Wayne, RP; Young, C, 2013) |
| "The ATHENA clinical trial enrolled 4,628 patients in 37 countries and evaluated the efficacy of dronedarone 400 mg twice daily versus placebo for the prevention of cardiovascular hospitalisation or death from any cause in patients with paroxysmal or persistent atrial fibrillation or atrial flutter." | 3.79 | Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland. ( Åkerborg, Ö; Bégo-Le Bagousse, G; Lindgren, P; Nilsson, J; Rosenquist, M, 2013) |
| "Amiodarone-induced thyrotoxicosis (AIT) is a clinical condition that is notoriously difficult to manage; the relative risk of adverse cardiovascular events in these patients compared with euthyroid patients is largely unknown." | 3.75 | Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome. ( Chow, WH; Fan, K; Jim, MH; Lee, CH; Mok, M; Shea, YF; Siu, CW; Tse, HF; Yiu, KH; Yuen, M, 2009) |
| "In patients with atrial fibrillation and congestive heart failure, a routine strategy of rhythm control does not reduce the rate of death from cardiovascular causes, as compared with a rate-control strategy." | 2.73 | Rhythm control versus rate control for atrial fibrillation and heart failure. ( Arnold, JM; Bourassa, MG; Buxton, AE; Camm, AJ; Connolly, SJ; Dorian, P; Dubuc, M; Ducharme, A; Guerra, PG; Hohnloser, SH; Lambert, J; Le Heuzey, JY; Lee, KL; Nattel, S; O'Hara, G; Pedersen, OD; Rouleau, JL; Roy, D; Singh, BN; Stevenson, LW; Stevenson, WG; Talajic, M; Thibault, B; Waldo, AL; Wyse, DG, 2008) |
| "Dronedarone has also been shown to reduce ventricular rate and the incidence of hospitalization due to cardiovascular events." | 2.47 | The management of patients with atrial fibrillation and dronedarone's place in therapy. ( Boiangiu, C; Cohen, M, 2011) |
| "Thyrotoxicosis is associated with increased cardiovascular morbidity and mortality, primarily due to heart failure and thromboembolism." | 2.43 | Thyrotoxicosis and the cardiovascular system. ( Brandle, M; Cattaneo, F; Roffi, M, 2005) |
| "Hypothyroidism has an inverse hemodynamic effect and is less noisy, usually limited to relative bradycardia." | 2.43 | [Cardiac consequences of clinical dysthyroidism. Pathophysiological, clinical, and epidemiologic data]. ( Brafin-Busch, MS; Goichot, B; Schlienger, JL; Vinzio, S, 2005) |
| "Thyrotoxicosis is associated with increased cardiovascular morbidity and mortality, primarily due to heart failure and thromboembolism." | 2.42 | Thyrotoxicosis and the cardiovascular system: subtle but serious effects. ( Cattaneo, F; Roffi, M; Topol, EJ, 2003) |
| "Thyrotoxicosis is a well defined clinical entity, determined by an increase of plasma levels of thyroid hormones (T3 and T4)." | 2.41 | [The management of thyrotoxicosis: a schematic approach]. ( Carapezzi, C; Corsello, SM; Papi, G, 2002) |
| "Eight patients were hospitalized for bradyarrhythmia." | 1.42 | Cardiovascular Events of Electrical Cardioversion Under Optimal Anticoagulation in Atrial Fibrillation: The Multicenter Analysis. ( Cho, I; Hartaigh, Bó; Hwang, ES; Joung, B; Lee, HY; Lee, MH; Mun, HS; Pak, HN; Park, JK; Shin, DG; Uhm, JS, 2015) |
| "Dronedarone is a new multichannel blocker, structurally related to amiodarone but free of iodine and less lipophilic and so expected to be free of iodine-related organ toxicity and tissue accumulation." | 1.36 | Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials. ( Duray, GZ; Hohnloser, SH; Schmitt, J, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (6.12) | 18.7374 |
| 1990's | 3 (6.12) | 18.2507 |
| 2000's | 26 (53.06) | 29.6817 |
| 2010's | 13 (26.53) | 24.3611 |
| 2020's | 4 (8.16) | 2.80 |
| Authors | Studies |
|---|---|
| Perveen, M | 1 |
| Hadia, NMA | 1 |
| Noreen, A | 1 |
| Mehmood, RF | 1 |
| Nasr, S | 1 |
| Yahia, IS | 1 |
| Khera, RA | 1 |
| Iqbal, J | 1 |
| Brutvan, T | 1 |
| Krátký, J | 1 |
| Ježková, J | 1 |
| Sileno, S | 1 |
| Chirila, RM | 1 |
| Harris, DM | 1 |
| Chiou, WR | 1 |
| Huang, CC | 1 |
| Lin, PL | 1 |
| Chuang, JY | 1 |
| Liu, LY | 1 |
| Su, MI | 1 |
| Liao, FC | 1 |
| Chen, CY | 1 |
| Kuo, JY | 1 |
| Tsai, CT | 1 |
| Wu, YJ | 1 |
| Lee, YH | 1 |
| Zafar, MU | 1 |
| Santos-Gallego, CG | 1 |
| Smith, DA | 1 |
| Halperin, JL | 2 |
| Badimon, JJ | 1 |
| Young, C | 1 |
| Maruthappu, M | 1 |
| Wayne, RP | 1 |
| Leaver, L | 1 |
| Murin, J | 2 |
| Naditch-Brûlé, L | 1 |
| Brette, S | 1 |
| Chiang, CE | 1 |
| O'Neill, J | 1 |
| Steg, PG | 1 |
| Shin, DG | 1 |
| Cho, I | 1 |
| Hartaigh, Bó | 1 |
| Mun, HS | 1 |
| Lee, HY | 1 |
| Hwang, ES | 1 |
| Park, JK | 1 |
| Uhm, JS | 1 |
| Pak, HN | 1 |
| Lee, MH | 1 |
| Joung, B | 1 |
| Pieper, PG | 1 |
| Glover, BM | 1 |
| Baranchuk, A | 1 |
| Roy, D | 1 |
| Talajic, M | 1 |
| Nattel, S | 1 |
| Wyse, DG | 1 |
| Dorian, P | 2 |
| Lee, KL | 1 |
| Bourassa, MG | 1 |
| Arnold, JM | 1 |
| Buxton, AE | 1 |
| Camm, AJ | 2 |
| Connolly, SJ | 3 |
| Dubuc, M | 1 |
| Ducharme, A | 1 |
| Guerra, PG | 1 |
| Hohnloser, SH | 4 |
| Lambert, J | 1 |
| Le Heuzey, JY | 1 |
| O'Hara, G | 1 |
| Pedersen, OD | 1 |
| Rouleau, JL | 1 |
| Singh, BN | 1 |
| Stevenson, LW | 1 |
| Stevenson, WG | 1 |
| Thibault, B | 1 |
| Waldo, AL | 1 |
| Køber, L | 1 |
| Torp-Pedersen, C | 3 |
| McMurray, JJ | 1 |
| Gøtzsche, O | 1 |
| Lévy, S | 1 |
| Crijns, H | 1 |
| Amlie, J | 1 |
| Carlsen, J | 1 |
| Shakur, R | 1 |
| Cockrum, E | 1 |
| Scott, D | 1 |
| Yiu, KH | 1 |
| Jim, MH | 1 |
| Siu, CW | 1 |
| Lee, CH | 1 |
| Yuen, M | 1 |
| Mok, M | 1 |
| Shea, YF | 1 |
| Fan, K | 1 |
| Tse, HF | 2 |
| Chow, WH | 1 |
| Lewalter, T | 1 |
| Nitschmann, S | 1 |
| Crijns, HJ | 1 |
| van Eickels, M | 1 |
| Gaudin, C | 1 |
| Page, RL | 1 |
| Floyd, J | 1 |
| Hatzitolios, A | 1 |
| Ntaios, G | 1 |
| Savopoulos, C | 1 |
| Duray, GZ | 1 |
| Schmitt, J | 1 |
| Gabr, RQ | 1 |
| Elsherbiny, ME | 1 |
| Somayaji, V | 1 |
| Pollak, PT | 1 |
| Brocks, DR | 1 |
| Joyner, C | 1 |
| Alings, M | 1 |
| Amerena, J | 1 |
| Atar, D | 1 |
| Avezum, Á | 1 |
| Blomström, P | 1 |
| Borggrefe, M | 1 |
| Budaj, A | 1 |
| Chen, SA | 1 |
| Ching, CK | 1 |
| Commerford, P | 1 |
| Dans, A | 1 |
| Davy, JM | 1 |
| Delacrétaz, E | 1 |
| Di Pasquale, G | 1 |
| Diaz, R | 1 |
| Flaker, G | 1 |
| Golitsyn, S | 1 |
| Gonzalez-Hermosillo, A | 1 |
| Granger, CB | 1 |
| Heidbüchel, H | 1 |
| Kautzner, J | 1 |
| Kim, JS | 1 |
| Lanas, F | 1 |
| Lewis, BS | 1 |
| Merino, JL | 1 |
| Morillo, C | 1 |
| Narasimhan, C | 1 |
| Paolasso, E | 1 |
| Parkhomenko, A | 1 |
| Peters, NS | 1 |
| Sim, KH | 1 |
| Stiles, MK | 1 |
| Tanomsup, S | 1 |
| Toivonen, L | 1 |
| Tomcsányi, J | 1 |
| Vardas, P | 1 |
| Vinereanu, D | 1 |
| Xavier, D | 1 |
| Zhu, J | 1 |
| Zhu, JR | 1 |
| Baret-Cormel, L | 1 |
| Weinling, E | 1 |
| Staiger, C | 1 |
| Yusuf, S | 1 |
| Chrolavicius, S | 1 |
| Afzal, R | 1 |
| Cohen, M | 1 |
| Boiangiu, C | 1 |
| Nilsson, J | 1 |
| Åkerborg, Ö | 1 |
| Bégo-Le Bagousse, G | 1 |
| Rosenquist, M | 1 |
| Lindgren, P | 1 |
| Salam, AM | 1 |
| Danzi, S | 1 |
| Klein, I | 1 |
| Gallik, DM | 1 |
| Singer, I | 1 |
| Meissner, MD | 1 |
| Molnar, J | 1 |
| Somberg, JC | 1 |
| Roffi, M | 2 |
| Cattaneo, F | 2 |
| Topol, EJ | 1 |
| Zyśko, D | 1 |
| Gajek, J | 1 |
| Simkó, J | 1 |
| Barta, K | 1 |
| Szabó, Z | 1 |
| Varga, E | 1 |
| Nagy, E | 1 |
| Lorincz, I | 1 |
| Brandle, M | 1 |
| Aasbo, JD | 1 |
| Lawrence, AT | 1 |
| Krishnan, K | 1 |
| Kim, MH | 1 |
| Trohman, RG | 1 |
| Vinzio, S | 1 |
| Brafin-Busch, MS | 1 |
| Schlienger, JL | 1 |
| Goichot, B | 1 |
| Nichols, N | 1 |
| Craycraft, ME | 1 |
| Pappone, C | 1 |
| Augello, G | 1 |
| Sala, S | 1 |
| Gugliotta, F | 1 |
| Vicedomini, G | 1 |
| Gulletta, S | 1 |
| Paglino, G | 1 |
| Mazzone, P | 1 |
| Sora, N | 1 |
| Greiss, I | 1 |
| Santagostino, A | 1 |
| LiVolsi, L | 1 |
| Pappone, N | 1 |
| Radinovic, A | 1 |
| Manguso, F | 1 |
| Santinelli, V | 1 |
| Gupta, R | 2 |
| Varma, Y | 1 |
| Yadav, BS | 1 |
| Gupta, S | 1 |
| Gupta, N | 1 |
| Friocourt, P | 1 |
| Coumel, P | 1 |
| Purcell, H | 1 |
| Ligtenberg, J | 1 |
| Tulleken, J | 1 |
| Zijlstra, J | 1 |
| Seto, W | 1 |
| Trope, A | 1 |
| Carfrae, L | 1 |
| Walker, S | 1 |
| Kinsara, AJ | 1 |
| Jeantet, M | 1 |
| Losay, J | 1 |
| Cassinat, G | 1 |
| Andral, J | 1 |
| Guize, L | 1 |
| de Pouvourville, G | 1 |
| Gombotz, H | 1 |
| Vicenzi, M | 1 |
| Mahla, E | 1 |
| Rehak, P | 1 |
| Metzler, H | 1 |
| Papi, G | 1 |
| Carapezzi, C | 1 |
| Corsello, SM | 1 |
| Wiersinga, WM | 1 |
| Trip, MD | 1 |
| van Beeren, MH | 1 |
| Plomp, TA | 1 |
| Oosting, H | 1 |
| Stanley, R | 1 |
| Comer, T | 1 |
| Taylor, JL | 1 |
| Saliba, D | 1 |
| Aghini-Lombardi, F | 1 |
| Lenziardi, M | 1 |
| Martino, E | 1 |
| Pinchera, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Atrial Fibrillation and Congestive Heart Failure (AF-CHF)Trial[NCT00597077] | Phase 4 | 1,376 participants (Actual) | Interventional | 2001-04-30 | Completed | ||
| A Randomised Trial to Assess Catheter Ablation Versus Rate-Control in the Management of Persistent Atrial Fibrillation in Chronic Heart Failure[NCT00878384] | 52 participants (Actual) | Interventional | 2009-04-30 | Completed | |||
| Pragmatic Randomized Clinical Trial of Early Dronedarone Versus Usual Care to Change and Improve Outcomes in Persons With First-Detected Atrial Fibrillation[NCT05130268] | Phase 4 | 3,000 participants (Anticipated) | Interventional | 2021-10-29 | Active, not recruiting | ||
| Using Time-dependent Intravenous Infusions of Amiodarone for Conversions to Sinus Rhythms in Patients With Paroxysmal Atrial Fibrillation[NCT03432663] | Phase 4 | 60 participants (Actual) | Interventional | 2008-08-01 | Completed | ||
| Antiarrhythmic Trial With Dronedarone in Moderate to Severe CHF Evaluating Morbidity Decrease[NCT00696631] | Phase 3 | 653 participants (Actual) | Interventional | 2002-06-30 | Terminated (stopped due to Terminated as the active treatment was associated with an increased hazard) | ||
| A Placebo-controlled,Double-blind,Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg Bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients With Atrial Fibrillation/Atrial Flutter (AF/AFL)[NCT00174785] | Phase 3 | 4,628 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Effect of Dronedarone on Atrial Fibrosis Progression and Atrial Fibrillation Recurrence Post Ablation: The EDORA Trial[NCT04704050] | Phase 4 | 22 participants (Actual) | Interventional | 2021-05-15 | Terminated (stopped due to Sponsor withdrew funding) | ||
| Acute Mechanical Response to Anti-arrhythmic Drug Therapy[NCT02575534] | 0 participants (Actual) | Interventional | 2015-10-31 | Withdrawn (stopped due to No enrollment in study.) | |||
| A Randomized, Double Blind, Placebo Controlled, Parallel Group Trial for Assessing the Clinical Benefit of Dronedarone 400mg BID on Top of Standard Therapy in Patients With Permanent Atrial Fibrillation and Additional Risk Factors[NCT01151137] | Phase 3 | 3,236 participants (Actual) | Interventional | 2010-07-31 | Terminated (stopped due to The study was stopped because of safety concerns) | ||
| A Controlled Randomized Trial of Circumferential Pulmonary Vein Ablation Versus Antiarrhythmic Drug Therapy in Treating Paroxysmal Atrial Fibrillation. The Ablation for Paroxysmal Atrial Fibrillation (APAF2) Trial[NCT00340314] | Phase 4 | 198 participants | Interventional | 2005-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The considered event is cardiovascular death, as assessed by the blinded adjudication of the Steering Committee. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 63 |
| Placebo | 90 |
The considered event is cardiovascular death, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 65 |
| Placebo | 94 |
The considered event is death from any cause. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 116 |
| Placebo | 139 |
The considered event is the first hospitalization for cardiovascular reason, as assessed by the Investigator. The analysis is performed on the time from randomization to this event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 675 |
| Placebo | 859 |
The primary event is the first hospitalization for cardiovascular reason or death from any cause, whichever is earlier, as assessed by the investigator. The primary efficacy analysis is performed on the time from randomization to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period. (NCT00174785)
Timeframe: minimum follow-up duration: 1 year ; maximum: 2.5 years
| Intervention | participants (Number) |
|---|---|
| Dronedarone 400mg Bid | 734 |
| Placebo | 917 |
Deaths were classified according to the primary cause of death. (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | participants (Number) | ||
|---|---|---|---|
| Any death | - Cardiovascular death | --- Cardiac arrhythmic death | |
| Dronedarone | 25 | 21 | 13 |
| Placebo | 13 | 10 | 4 |
AE are any unfavorable and unintended sign, symptom, syndrome, or illness observed by the investigator or reported by the participant during the study. (NCT01151137)
Timeframe: from first study drug intake up to 10 days after the last study drug intake
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| Any AE | - Any serious AE | - Any AE leading to death | - Any AE leading to treatment discontinuation | - Any AE leading to hospitalization | |
| Dronedarone | 797 | 113 | 4 | 212 | 95 |
| Placebo | 600 | 77 | 0 | 80 | 71 |
(NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| MI or unstable angina pectoris | - MI | Stroke | - Ischemic stroke | Systemic arterial embolism | Episode of heart failure | - Hospitalization due to heart failure | Unplanned hospitalization for cardiovascular cause | |
| Dronedarone | 15 | 3 | 23 | 18 | 1 | 115 | 43 | 113 |
| Placebo | 8 | 2 | 10 | 9 | 0 | 55 | 24 | 59 |
"First co-primary outcome was defined as the first event among stroke, systemic arterial embolism, Myocardial Infarctions [MI], or cardiovascular death.~Second co-primary outcome was defined as the first event among unscheduled cardiovascular hospitalization or death from any cause.~Both co-primary outcomes were determined based on the central review and adjudication by a blinded Adjudication Committee of all reported deaths (from any cause), MI, systemic arterial embolisms, strokes, Transient Ischemic Attacks [TIA], Heart Failure hospitalization and unplanned hospitalisations for cardiovascular cause." (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | participants (Number) | |
|---|---|---|
| First co-primary endpoint | Second co-primary endpoint | |
| Dronedarone | 43 | 127 |
| Placebo | 19 | 67 |
"Time to cardiovascular death was defined as the time from randomization to the death.~Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.~95% confidence interval was computed at each time-point using Greenwood's variance estimation." (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | proportion of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Cumulative incidence at 14 days | Cumulative incidence at 30 days | Cumulative incidence at 90 days | Cumulative incidence at 180 days | Cumulative incidence at 270 days | Cumulative incidence at 360 days | |
| Dronedarone | 0.003 | 0.005 | 0.008 | 0.022 | 0.026 | 0.026 |
| Placebo | 0.001 | 0.003 | 0.004 | 0.004 | 0.027 | 0.027 |
"Time to first co-primary outcome was defined as the time from randomization to the first event among stroke, systemic arterial embolism, MI or cardiovascular death.~Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.~95% confidence interval was computed at each time-point using Greenwood's variance estimation." (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | proportion of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Cumulative incidence at 14 days | Cumulative incidence at 30 days | Cumulative incidence at 90 days | Cumulative incidence at 180 days | Cumulative incidence at 270 days | Cumulative incidence at 360 days | |
| Dronedarone | 0.009 | 0.013 | 0.021 | 0.042 | 0.045 | 0.045 |
| Placebo | 0.002 | 0.003 | 0.007 | 0.013 | 0.038 | 0.038 |
"Time to second co-primary outcome was defined as the time from randomization to the first event among unscheduled cardiovascular hospitalization or death from any cause.~Cumulative incidence function in each treatment group was calculated using non-parametric Kaplan-Meier estimate.~95% confidence interval was computed at each time-point using Greenwood's variance estimation." (NCT01151137)
Timeframe: From randomization up to the CSED which occurred at study termination (maximum follow-up of 1 year)
| Intervention | proportion of participants (Number) | |||||
|---|---|---|---|---|---|---|
| Cumulative incidence at 14 days | Cumulative incidence at 30 days | Cumulative incidence at 90 days | Cumulative incidence at 180 days | Cumulative incidence at 270 days | Cumulative incidence at 360 days | |
| Dronedarone | 0.020 | 0.034 | 0.069 | 0.110 | 0.137 | 0.137 |
| Placebo | 0.005 | 0.014 | 0.033 | 0.059 | 0.099 | 0.099 |
16 reviews available for amiodarone and Cardiovascular Diseases
| Article | Year |
|---|---|
Use of statins, amiodarone, direct oral anticoagulants and NSAIDs in chronic liver disease: a guide for general clinicians.
Topics: Administration, Oral; Amiodarone; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; A | 2020 |
Use of medication for cardiovascular disease during pregnancy.
Topics: Amiodarone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascul | 2015 |
Amiodarone: pharmacological profile, animal-model experimental data and clinical use. How important is the vasodilating effect?
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Cardiovascular Diseases; Drug Interactions; Humans; Mod | 2009 |
The management of patients with atrial fibrillation and dronedarone's place in therapy.
Topics: Age Factors; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Cardiovascular | 2011 |
Dronedarone in atrial fibrillation: the aftermath of the PALLAS trial.
Topics: Age Factors; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Diseases; Drone | 2012 |
Thyroid hormone-regulated cardiac gene expression and cardiovascular disease.
Topics: Amiodarone; Animals; Cardiovascular Diseases; Cytokines; Gene Expression Regulation; Humans; Hypothy | 2002 |
Thyrotoxicosis and the cardiovascular system: subtle but serious effects.
Topics: Adrenergic beta-Antagonists; Amiodarone; Antithyroid Agents; Calcium Channel Blockers; Cardiovascula | 2003 |
[Thyroid and cardiovascular disorders].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiovascular Diseases; Coronary Artery B | 2004 |
[Cardiovascular manifestations of thyrotoxicosis and thyroid dysfunction caused by amiodarone].
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Diseases; Heart Failure; Hum | 2004 |
Thyrotoxicosis and the cardiovascular system.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiovascula | 2005 |
Amiodarone prophylaxis reduces major cardiovascular morbidity and length of stay after cardiac surgery: a meta-analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardi | 2005 |
[Cardiac consequences of clinical dysthyroidism. Pathophysiological, clinical, and epidemiologic data].
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; | 2005 |
Hypothyroidism and cardiovascular disease.
Topics: Amiodarone; Cardiovascular Agents; Cardiovascular Diseases; Drug Interactions; Humans; Hypothyroidis | 2005 |
Cardiovascular changes in thyroid disorder.
Topics: Amiodarone; Cardiovascular Diseases; Humans; Hyperthyroidism; Hypothyroidism; Risk Factors; Thyroid | 2006 |
[Side effects of amiodarone].
Topics: Amiodarone; Benzofurans; Brain Diseases; Cardiovascular Diseases; Eye Diseases; Humans; Skin Disease | 1983 |
[The management of thyrotoxicosis: a schematic approach].
Topics: Adenoma; Adrenal Cortex Hormones; Adult; Aged; Amiodarone; Antithyroid Agents; Cardiovascular Diseas | 2002 |
6 trials available for amiodarone and Cardiovascular Diseases
| Article | Year |
|---|---|
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Rhythm control versus rate control for atrial fibrillation and heart failure.
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2008 |
Increased mortality after dronedarone therapy for severe heart failure.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Cardiovascular Diseases; Cause o | 2008 |
Increased mortality after dronedarone therapy for severe heart failure.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Cardiovascular Diseases; Cause o | 2008 |
Increased mortality after dronedarone therapy for severe heart failure.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Cardiovascular Diseases; Cause o | 2008 |
Increased mortality after dronedarone therapy for severe heart failure.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Cardiovascular Diseases; Cause o | 2008 |
Effect of dronedarone on cardiovascular events in atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiovascular Diseases; | 2009 |
Effect of dronedarone on cardiovascular events in atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiovascular Diseases; | 2009 |
Effect of dronedarone on cardiovascular events in atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiovascular Diseases; | 2009 |
Effect of dronedarone on cardiovascular events in atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiovascular Diseases; | 2009 |
Effect of dronedarone on cardiovascular events in atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiovascular Diseases; | 2009 |
Effect of dronedarone on cardiovascular events in atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiovascular Diseases; | 2009 |
Effect of dronedarone on cardiovascular events in atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiovascular Diseases; | 2009 |
Effect of dronedarone on cardiovascular events in atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiovascular Diseases; | 2009 |
Effect of dronedarone on cardiovascular events in atrial fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiovascular Diseases; | 2009 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
Dronedarone in high-risk permanent atrial fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Ca | 2011 |
A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study.
Topics: Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Diseases; | 2006 |
First clinical experience with the rapid-, short-acting amiodarone derivative E 047/1 after cardiac surgery.
Topics: Aged; Amiodarone; Analysis of Variance; Anti-Arrhythmia Agents; Area Under Curve; Arrhythmias, Cardi | 2002 |
27 other studies available for amiodarone and Cardiovascular Diseases
| Article | Year |
|---|---|
Controlled supramolecular interactions for targeted release of Amiodarone drug through Graphyne to treat cardiovascular diseases: An in silico study.
Topics: Amiodarone; Cardiovascular Diseases; Drug Carriers; Drug Delivery Systems; Humans; Nanostructures | 2023 |
Pharmacologically induced thyreopathy in patients with cardiovascular disease.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiovascular Diseases; Humans; Hyperthyroidism; Hypothyroidism | 2020 |
Safety and Effectiveness of Rivaroxaban in Combination with Various Antiarrhythmic Drugs in Patients with Non-Permanent Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Dis | 2021 |
Dronedarone exerts anticoagulant and antiplatelet effects independently of its antiarrhythmic actions.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Anticoagulants; Blood Coagulation; Blood Coagulation Tests | 2017 |
Reversible acute kidney injury requiring haemodialysis five days after starting dronedarone in a stable 71-year-old man at risk of cardiovascular polypharmacy.
Topics: Acute Kidney Injury; Aged; Amiodarone; Anti-Arrhythmia Agents; Antihypertensive Agents; Cardiovascul | 2013 |
Clinical characteristics, management, and control of permanent vs. nonpermanent atrial fibrillation: insights from the RealiseAF survey.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Dis | 2014 |
Cardiovascular Events of Electrical Cardioversion Under Optimal Anticoagulation in Atrial Fibrillation: The Multicenter Analysis.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bradycardia; Cardiovascular Diseases; | 2015 |
Amiodarone for atrial fibrillation: Friend or foe?
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Diseases; Humans | 2015 |
Cardiovascular therapeutics.
Topics: Adrenergic beta-Antagonists; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Ag | 2008 |
Amiodarone-induced thyrotoxicosis is a predictor of adverse cardiovascular outcome.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiovascular Diseases; Female; Humans; Male; Midd | 2009 |
[Therapeutic aims for atrial fibrillation in patients with heart failure].
Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhyt | 2009 |
Dronedarone in atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Diseases; Dronedarone; Hospi | 2009 |
Dronedarone therapy in atrial fibrillation: a summary of recent controlled trials.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Cardiovascular Dis | 2010 |
A liquid chromatography-mass spectrometry method for nicotine and cotinine; utility in screening tobacco exposure in patients taking amiodarone.
Topics: Amiodarone; Cardiovascular Diseases; Chromatography, Reverse-Phase; Cotinine; Humans; Liquid-Liquid | 2011 |
Dronedarone trial stopped due to excess mortality.
Topics: Amiodarone; Atrial Fibrillation; Cardiovascular Diseases; Controlled Clinical Trials as Topic; Drone | 2011 |
Cost-effectiveness analysis of dronedarone versus other anti-arrhythmic drugs for the treatment of atrial fibrillation--results for Canada, Italy, Sweden and Switzerland.
Topics: Age Factors; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Canada; Cardiovascular Disease | 2013 |
Hemodynamic and surface electrocardiographic effects of a new aqueous formulation of intravenous amiodarone.
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Cardiovascular Diseases; Electro | 2002 |
Summaries for patients. Potential benefits of amiodarone for patients undergoing open-heart surgery.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Cardi | 2005 |
Amiodarone prophylaxis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiac Surgical Procedures; Cardiovascular Diseases; Humans; Le | 2006 |
Conference review: scientific session of the American College of Cardiology 1996.
Topics: Amiodarone; Anti-Arrhythmia Agents; Anticholesteremic Agents; Anticoagulants; Biomarkers; Cardiology | 1996 |
Plasmapheresis in thyrotoxicosis.
Topics: Adult; Amiodarone; Cardiovascular Diseases; Contraindications; Humans; Male; Middle Aged; Plasmapher | 1999 |
Visual compatibility of sodium nitroprusside with other injectable medications given to pediatric patients.
Topics: Amiodarone; Cardiovascular Diseases; Catheterization, Central Venous; Chemical Precipitation; Child; | 2001 |
Amiodarone in the new ACLS guidelines.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Cardiovascular Diseases; Emergenc | 2001 |
[Paroxysmal atrial fibrillation in community medicine: management intentions and cost estimates].
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiovascular Dis | 2001 |
An increase in plasma cholesterol independent of thyroid function during long-term amiodarone therapy. A dose-dependent relationship.
Topics: Adult; Aged; Amiodarone; Cardiovascular Diseases; Cholesterol; Dose-Response Relationship, Drug; Fem | 1991 |
Mexiletine-theophylline interaction.
Topics: Aged; Amiodarone; Cardiovascular Diseases; Dose-Response Relationship, Drug; Drug Interactions; Drug | 1989 |
[Amiodarone and thyroid function].
Topics: Adult; Aged; Amiodarone; Cardiovascular Diseases; Drug Administration Schedule; Female; Humans; Hype | 1987 |